DTAS Workflow vs Standard Triage for Stroke Treatment
Trial Summary
What is the purpose of this trial?
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on oral anticoagulant therapy with an INR greater than 3.0, you may be excluded from participating.
What data supports the effectiveness of the treatment Direct to Angio Suite (DTAS) for stroke?
Research shows that the Direct to Angio Suite (DTAS) approach for stroke treatment can significantly reduce the time to reperfusion, which is crucial for improving patient outcomes. Studies indicate that faster treatment times are associated with better recovery and reduced disability in stroke patients.12345
Is the Direct to Angio Suite (DTAS) approach generally safe for humans?
The Direct to Angio Suite (DTAS) approach has been studied in stroke patients, and while it aims to improve treatment times, some patients showed intracerebral hemorrhage (bleeding in the brain) on imaging. This suggests that while the approach is generally used to improve outcomes, there are potential safety concerns that need to be considered.23467
How is the DTAS Workflow treatment for stroke different from other treatments?
The DTAS Workflow treatment for stroke is unique because it involves taking patients directly to the angio suite for immediate imaging and potential treatment, using Philips' CBCT (Cone Beam Computed Tomography) technology, which can speed up the process compared to standard triage methods that may involve multiple steps and delays.89101112
Research Team
Raul G Nogueira
Principal Investigator
UPMC Stroke Institute, Pittsburgh
Marc Ribo
Principal Investigator
Vall d'Hebron University Hospital, Barcelona
Eligibility Criteria
The WE-TRUST trial is for adults who've had a stroke, can give consent, and have no major disability from past strokes. They must arrive at the hospital within 6 hours of their stroke starting and have a certain severity score on a neurological scale. People with in-hospital strokes, severe conditions or high blood pressure not suitable for thrombolysis, pregnant women, Philips employees and their families are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo the Direct to Angio Suite (DTAS) workflow for stroke treatment, utilizing Cone-Beam CT (CBCT) for triage and immediate intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment, with primary outcome measures assessed at 90 ± 14 days
Safety Monitoring
Monitoring for adverse events and device deficiencies from enrollment until hospital discharge
Treatment Details
Interventions
- Conventional CT/MR triage (Procedure)
- Direct to Angio Suite (DTAS) Philips' CBCT triage (Device)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Philips Healthcare
Lead Sponsor
Roy Jakobs
Philips Healthcare
Chief Executive Officer since 2022
Master's in Business Administration from Radboud University Nijmegen and Università degli Studi di Bologna
Dr. Roy Jakobs
Philips Healthcare
Chief Medical Officer
MD from McGill University
Philips Clinical & Medical Affairs Global
Lead Sponsor
Roy Jakobs
Philips Clinical & Medical Affairs Global
Chief Executive Officer since 2022
MBA from Erasmus University Rotterdam
Carla Goulart Peron
Philips Clinical & Medical Affairs Global
Chief Medical Officer since 2023
MD from an unspecified institution